These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28067632)

  • 1. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
    Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
    Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
    J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.
    Liu Z; Mao X; Yu K; Suo C; Jin L; Zhang T; Chen X
    J Viral Hepat; 2020 Jun; 27(6):585-592. PubMed ID: 32049405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.
    Ren S; Wei F; Jin Y; Lu J; He Z; Ma L; Zheng Y; Wang J; Chen X
    Antivir Ther; 2020; 25(5):245-255. PubMed ID: 32936785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    Wang GP; Schnell GL; Kort JJ; Sidhu GS; Schuster L; Tripathi RL; Larsen L; Michael LC; Bergquist K; Magee A; Patel CB; Whitlock JA; Tamashiro R; Peter JA; Fried MW; Nelson DR
    J Hepatol; 2021 Oct; 75(4):820-828. PubMed ID: 34023351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
    McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
    Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
    Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
    Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
    Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
    Kileng H; Kjellin M; Akaberi D; Bergfors A; Duberg AS; Wesslén L; Danielsson A; Gangsøy Kristiansen M; Gutteberg T; Goll R; Lannergård A; Lennerstrand J
    Scand J Gastroenterol; 2018; 53(10-11):1347-1353. PubMed ID: 30394152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
    Kim KA; Lee S; Park HJ; Jang ES; Lee YJ; Cho SB; Kim YS; Kim IH; Lee BS; Chung WJ; Ahn SH; Kim S; Jeong SH
    Clin Mol Hepatol; 2023 Apr; 29(2):496-509. PubMed ID: 36880209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.
    Gozlan Y; Bucris E; Shirazi R; Rakovsky A; Ben-Ari Z; Davidov Y; Veizman E; Saadi T; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Katchman H; Menachem Y; Safadi R; Galun E; Zuckerman E; Nimer A; Hazzan R; Maor Y; Saif AM; Etzion O; Lurie Y; Mendelson E; Mor O
    Antivir Ther; 2019; 24(3):221-228. PubMed ID: 30880684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
    Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
    Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors.
    Jiang X; Lv X; Chang L; Yan Y; Ji H; Sun H; Guo F; Rodgers MA; Yin P; Wang L
    Antiviral Res; 2020 Sep; 181():104871. PubMed ID: 32717286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
    Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
    Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.
    Lahser F; Galloway A; Hwang P; Palcza J; Brunhofer J; Wahl J; Robertson M; Barr E; Black T; Asante-Appiah E; Haber B
    Antivir Ther; 2018; 23(7):593-603. PubMed ID: 30038064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.